NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-07-23
Reading COLL? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a stable growth opportunity in the healthcare sector. The current thesis is intact, supported by strong recent financial performance and management's focus on revenue growth and operating income enhancement.
The valuation is considered neutral, with COLL priced relatively cheap compared to its peers. The market appears to have a low expectations gap, indicating that it is not overly optimistic about future performance.
COLL's fundamentals are likely to continue improving, as management is on track with its priorities, including revenue growth and operating income enhancement. However, there is a near-term risk of missing earnings expectations, given the high-miss-rate nature of the industry.
The long-term thesis hinges on the performance of sector bellwethers like HLN, TEVA, and ZTS. If these companies continue to perform well, COLL could benefit from the positive momentum in the healthcare sector.
Overall, COLL shows promise with strong management and financials, but it faces risks that could impact its trajectory. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. This improvement is driven by the latest earnings beat, which indicates strong financial performance and supports the thesis that the reasons to own COLL remain intact. There are no current threats impacting this assessment.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Meeting this target would prove the financial gains from the AZSTARYS acquisition.
Confirms:Adjusted EBITDA for 2026 reaches $500 million or more.
Disproves:Adjusted EBITDA for 2026 is less than $475 million.
Why it matters: Steady revenue growth shows a strong market position and good product strategies.
Confirms:Quarterly revenue growth exceeds 9% YoY for the next two quarters.
Disproves:Quarterly revenue growth falls below 9% YoY for two consecutive quarters.
Why it matters: Closing the acquisition on time would support Collegium's growth plan and improve its ADHD products.
Confirms:The acquisition of AZSTARYS is completed by the end of Q2 2026.
Disproves:The acquisition is delayed past Q2 2026. This is due to regulatory issues.
Why it matters: If operating income stays the same or goes down, it may show cost management issues. This would hurt overall profits.
Confirms:Operating income growth is below 10% year over year in the next earnings release.
Disproves:Operating income growth exceeds 10% year over year in the next earnings release.
Why it matters: Key executives leaving may change what Collegium plans to do and how it performs.
Confirms:New leaders that help improve company plans and operations.
Disproves:There may be ongoing problems or bad results after the executive changes.
Why it matters: This will show if Collegium is meeting its growth targets after the acquisition.
Confirms one read:Q2 earnings report shows revenue growth above 10% year over year.
Confirms the other:Q2 earnings report shows revenue growth below 5% year over year.
Why it matters: High growth in JORNAY PM shows strong market demand and good sales strategies.
Confirms:JORNAY PM revenue growth exceeds 30% year-over-year in the next quarter.
Disproves:JORNAY PM revenue growth drops below 20% year-over-year.
Why it matters: A drop in revenue growth could signal a slowdown in Collegium's performance. This would raise concerns about the impact of the Corium acquisition on future sales.
Confirms:Revenue growth reported below 10% year over year in the next earnings release.
Disproves:Revenue growth remains above 10% year over year in the next earnings release.
Why it matters: This report will provide insights on revenue growth and the impact of the AZSTARYS acquisition.
Confirms one read:Collegium reports Q2 2026 earnings. Product revenues are over $220 million.
Confirms the other:Collegium reports Q2 2026 earnings. Product revenues are below $220 million.
Why it matters: Growth in operating income shows the company is managing costs well.
Confirms:Operating income for Q2 2026 is over $30.9 million.
Disproves:Operating income for Q2 2026 is below $30.9 million.
Why it matters: Strong revenue from AZSTARYS shows the acquisition's value and growth potential.
Confirms:AZSTARYS makes over $60 million in net revenue in the second half of 2026.
Disproves:AZSTARYS revenue falls below $50 million in the second half of 2026.
